论文部分内容阅读
胰高血糖素样肽-1(GLP-1)为末端空肠、回肠及结肠中L细胞分泌的葡萄糖依赖性的内源性肠促胰岛素分泌激素,依其可与胰岛β细胞膜上受体特异性结合促进β细胞增殖、分化、抑制其凋亡,增加胰岛β细胞数量,改善胰岛β细胞功能的作用而被视为治疗2型糖尿病(T2DM)新靶点的又一突破性发现。本文就目前FDA批准上市的胰高血糖素样肽-1受体激动剂(GLP-1 RAs)有关受体分布特点、作用机制、临床疗效及不良反应作一综述。
Glucagon-like peptide-1 (GLP-1) is a glucose-dependent endogenous incretin secretagogue secreted by L cells in the terminal jejunum, ileum and colon and can specifically bind to receptors on the islet β-cell membrane Combined with the promotion of β-cell proliferation, differentiation, inhibition of apoptosis, increase the number of islet β cells and improve the function of pancreatic β-cell function is considered a new target for the treatment of type 2 diabetes (T2DM) another breakthrough discovery. This review summarizes the distribution characteristics, mechanism of action, clinical efficacy and adverse reactions of GLP-1 receptor agonists (GLP-1 RAs) currently approved by the FDA.